Oxford Nanopore Technologies Limited (ONTTF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Oxford Nanopore Technologies Limited $0.36, price $3.04, upside -88.2%, quality 45 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Oxford Nanopore Technologies Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $1.11 – $9.95 · fair‑value band $0.2400 – $0.4500 · the $3.04 price screens above the $0.3600 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow Oxford Nanopore Technologies in your weekly email
Every Wednesday you see whether Oxford Nanopore Technologies is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA.
Show more
Oxford Nanopore Technologies plc engages in the research, development, manufacture, and commercialization of a novel generation of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) sequencing technology that allows analysis of DNA or RNA. The company offers MinION Mk 1D, a portable device for DNA and RNA sequencing; and GridION and GridION Q, a compact bench top device that delivers a version of hardware, software, and chemistry. It also provides PromethION products, such as PromethION 2, PromethION 24, and PromethION 48. The company has a collaboration with Cepheid to develop and commercialize automated infectious disease sequencing solutions. It operates in the region of Americas, Europe, the Middle East, Africa, India, and the Asia Pacific. The company was formerly known as Oxford NanoLabs Limited and changed its name to Oxford Nanopore Technologies plc in May 2008. Oxford Nanopore Technologies plc was incorporated in 2005 and is headquartered in Oxford, the United Kingdom.
Stock analysis
Oxford Nanopore Technologies Limited (ONTTF) currently trades at $3.04, while our model-based Fair Value estimate is $0.3600, 88.2% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $0.2400 (bear) to $0.4500 (bull), the price of $3.04 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 45/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Oxford Nanopore Technologies Limited reported revenue of £224M in FY2025 versus £134M in FY2021, a compound +13.8%/yr. Reported net income was −£145M in FY2025.
Key figures
Market cap $2.9B · P/S ratio 6.85 · EPS (TTM) $−0.2000 · Net margin −64.9% · Return on equity −27.7% · Return on assets (EBIT) −18.9% · Operating margin −48.7% · Revenue (TTM) £224M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 116% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −88%, ONTTF screens richer than that median.
Fair Value models
Bear $0.2400Fair Value $0.3600Bull $0.4500
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.36/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+22.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.5%
Start year 2020 (pandemic). Over 10 years: +76.9% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+75.5%
’12
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−64.2% (2020) → −57.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Oxford Nanopore Technologies Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Above median
Fair Value upside−87.2% · Bottom 25%
Profitability
Return on assets−12.0% · Below median
Net margin (TTM)−64.9% · Bottom 25%
Operating margin (TTM)−48.7% · Bottom 25%
Growth and dividend
Revenue growth19.4% · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B5.83× · Priciest 25%
P/S (TTM)12.06× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)97· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 22
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Oxford Nanopore Technologies Limited (ONTTF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.3600 versus a price of $3.04, about −88% upside (overvalued).
What is the fair value of ONTTF?
Our model-based fair value for Oxford Nanopore Technologies Limited is $0.3600 (as of Sep 24, 2026), built from audited fundamentals. The current price: $3.04.
What is the quality score of ONTTF?
Oxford Nanopore Technologies Limited has a Quality Score of 45/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Oxford Nanopore Technologies Limited (ONTTF)?
Our model-based price target is the fair value of $0.3600 (as of Sep 24, 2026) from 1 valuation models. Cautious scenario $0.2400, optimistic scenario $0.4500. It is a calculation from audited fundamentals, not an analyst target.
What is the Oxford Nanopore Technologies Limited stock forecast for 2026?
Our models put fair value at $0.3600, about −88% upside versus a price of $3.04 (overvalued). Cautious scenario $0.2400, optimistic scenario $0.4500. The calculation is refreshed regularly with new filings.
What is the revenue of Oxford Nanopore Technologies Limited (ONTTF)?
Oxford Nanopore Technologies Limited reported trailing-twelve-month revenue of about £224M (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of Oxford Nanopore Technologies Limited (ONTTF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Oxford Nanopore Technologies Limited it is $0.3600 per share (as of Sep 24, 2026), against a price of $3.04. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Oxford Nanopore Technologies Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, ONTTF trades above its calculated fair value: price $3.04, fair value $0.3600, a gap of about −88% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ONTTF?
No. The price is what the market pays today ($3.04); the fair value is what the company's own numbers justify ($0.3600). For Oxford Nanopore Technologies Limited the two are $2.68 per share apart. That gap is exactly why we show both numbers side by side.
How much is Oxford Nanopore Technologies Limited worth?
The market values Oxford Nanopore Technologies Limited at about $2.9B (market capitalisation, as of Sep 24, 2026). Per share that is $3.04; our models calculate a fair value of $0.3600 per share.
What do the bullish and bearish scenarios say about ONTTF?
Our models span a range for Oxford Nanopore Technologies Limited: cautious scenario $0.2400, base $0.3600, optimistic $0.4500 per share (as of Sep 24, 2026, price $3.04). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Oxford Nanopore Technologies Limited (ONTTF)?
Balance-sheet figures for Oxford Nanopore Technologies Limited (as of Sep 24, 2026): return on equity −27.7%. They feed the Quality Score of 45/100, which measures business quality independently of the share price.
How far is ONTTF from its 52-week high?
Oxford Nanopore Technologies Limited trades at $3.04, at its 52-week high of $3.04 and 116% above the low of $1.41 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3600 is for.
Which stocks are comparable to Oxford Nanopore Technologies Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Oxford Nanopore Technologies Limited stock attractive at the current price?
The data as of Sep 24, 2026: price $3.04, calculated fair value $0.3600 (−88%), Quality Score 45/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ONTTF calculated?
We run Oxford Nanopore Technologies Limited through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.3600, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Oxford Nanopore Technologies Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Oxford Nanopore Technologies Limited (ONTTF)?
The closing price on Oct 2, 2026 was $3.04. Our model-based fair value is $0.3600, about −88% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Oxford Nanopore Technologies Limited right now?
The price sits above even our optimistic bull case ($0.4500). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (45/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($0.2400 to $0.4500) leaves room in how you read the outcome.
Key figures of Oxford Nanopore Technologies Limited
How large is the market capitalisation of Oxford Nanopore Technologies Limited (ONTTF)?
The market capitalisation of Oxford Nanopore Technologies Limited is $2.9B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Oxford Nanopore Technologies Limited (ONTTF)?
The price-to-sales ratio of Oxford Nanopore Technologies Limited is 6.85 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Oxford Nanopore Technologies Limited (ONTTF)?
Earnings per share at Oxford Nanopore Technologies Limited are $−0.2000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Oxford Nanopore Technologies Limited (ONTTF)?
The net margin of Oxford Nanopore Technologies Limited is −64.9% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Oxford Nanopore Technologies Limited (ONTTF)?
The return on equity (ROE) of Oxford Nanopore Technologies Limited is −27.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Oxford Nanopore Technologies Limited (ONTTF)?
On an EBIT basis the return on assets of Oxford Nanopore Technologies Limited is −18.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Oxford Nanopore Technologies Limited (ONTTF)?
The operating margin of Oxford Nanopore Technologies Limited is −48.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Oxford Nanopore Technologies Limited (ONTTF)?
Revenue at Oxford Nanopore Technologies Limited is growing +19.4% versus a year earlier (3y avg +4.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Oxford Nanopore Technologies Limited (ONTTF) generate?
The free cash flow of Oxford Nanopore Technologies Limited is −£66.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Oxford Nanopore Technologies Limited (ONTTF) hold?
Oxford Nanopore Technologies Limited holds more cash than debt, £140M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Oxford Nanopore Technologies Limited in the live analysis
One click puts Oxford Nanopore Technologies Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 24, 2026